| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 439 | 2024 | 1141 | 65.740 |
Why?
|
| Antihypertensive Agents | 284 | 2024 | 521 | 42.490 |
Why?
|
| Diabetic Nephropathies | 161 | 2023 | 248 | 33.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 237 | 2024 | 1373 | 32.790 |
Why?
|
| Blood Pressure | 273 | 2024 | 1143 | 30.900 |
Why?
|
| Renal Insufficiency, Chronic | 134 | 2024 | 350 | 30.880 |
Why?
|
| Cardiovascular Diseases | 159 | 2023 | 827 | 19.540 |
Why?
|
| Kidney Diseases | 100 | 2022 | 418 | 18.680 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 142 | 2023 | 231 | 17.010 |
Why?
|
| Diabetes Mellitus | 77 | 2023 | 806 | 16.000 |
Why?
|
| Albuminuria | 105 | 2023 | 153 | 15.960 |
Why?
|
| Kidney Failure, Chronic | 97 | 2023 | 509 | 14.940 |
Why?
|
| Kidney | 117 | 2024 | 1241 | 14.610 |
Why?
|
| Endocrinology | 17 | 2022 | 66 | 11.780 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 43 | 2024 | 59 | 9.970 |
Why?
|
| Sympathectomy | 25 | 2023 | 42 | 9.280 |
Why?
|
| Calcium Channel Blockers | 83 | 2021 | 203 | 9.070 |
Why?
|
| Humans | 891 | 2024 | 86601 | 8.810 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 56 | 2023 | 83 | 8.700 |
Why?
|
| Renin-Angiotensin System | 54 | 2023 | 133 | 8.230 |
Why?
|
| Adrenergic beta-Antagonists | 55 | 2020 | 152 | 8.110 |
Why?
|
| Glomerular Filtration Rate | 112 | 2023 | 384 | 7.950 |
Why?
|
| Angiotensin Receptor Antagonists | 43 | 2023 | 80 | 7.620 |
Why?
|
| Heart Failure | 71 | 2024 | 1203 | 7.600 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 45 | 2018 | 90 | 7.570 |
Why?
|
| Hyperkalemia | 30 | 2021 | 43 | 7.440 |
Why?
|
| Hypertension, Renal | 21 | 2022 | 40 | 7.050 |
Why?
|
| Hypoglycemic Agents | 41 | 2023 | 378 | 6.870 |
Why?
|
| Drug Therapy, Combination | 108 | 2021 | 894 | 5.720 |
Why?
|
| Double-Blind Method | 128 | 2024 | 1823 | 5.650 |
Why?
|
| Benzimidazoles | 28 | 2018 | 140 | 5.550 |
Why?
|
| Proteinuria | 41 | 2019 | 107 | 5.430 |
Why?
|
| Risk Factors | 167 | 2023 | 5416 | 5.190 |
Why?
|
| Practice Guidelines as Topic | 45 | 2020 | 1034 | 5.060 |
Why?
|
| Diabetes Complications | 37 | 2020 | 207 | 5.040 |
Why?
|
| Societies, Medical | 34 | 2022 | 572 | 5.020 |
Why?
|
| Hydrochlorothiazide | 37 | 2018 | 76 | 5.020 |
Why?
|
| Diabetic Angiopathies | 26 | 2019 | 62 | 5.010 |
Why?
|
| Renal Artery | 14 | 2022 | 64 | 4.740 |
Why?
|
| Naphthyridines | 26 | 2024 | 53 | 4.660 |
Why?
|
| Tetrazoles | 26 | 2023 | 50 | 4.550 |
Why?
|
| Piperidines | 21 | 2022 | 181 | 4.540 |
Why?
|
| Middle Aged | 288 | 2024 | 25017 | 4.200 |
Why?
|
| Diuretics | 51 | 2022 | 124 | 4.190 |
Why?
|
| Treatment Outcome | 154 | 2023 | 7988 | 4.050 |
Why?
|
| Potassium | 32 | 2021 | 281 | 4.040 |
Why?
|
| Amlodipine | 32 | 2018 | 37 | 4.040 |
Why?
|
| Blood Pressure Determination | 32 | 2020 | 90 | 4.020 |
Why?
|
| Renal Dialysis | 23 | 2023 | 355 | 4.000 |
Why?
|
| Creatinine | 45 | 2023 | 338 | 3.980 |
Why?
|
| Male | 348 | 2024 | 40956 | 3.940 |
Why?
|
| Aged | 247 | 2023 | 18402 | 3.920 |
Why?
|
| Canagliflozin | 31 | 2023 | 31 | 3.920 |
Why?
|
| Female | 353 | 2024 | 44507 | 3.890 |
Why?
|
| Disease Progression | 77 | 2023 | 1531 | 3.890 |
Why?
|
| Randomized Controlled Trials as Topic | 52 | 2021 | 864 | 3.650 |
Why?
|
| Oxadiazoles | 14 | 2018 | 46 | 3.440 |
Why?
|
| Standard of Care | 19 | 2022 | 78 | 3.390 |
Why?
|
| Sympathetic Nervous System | 15 | 2018 | 104 | 3.340 |
Why?
|
| Reference Standards | 16 | 2022 | 159 | 3.160 |
Why?
|
| Metabolic Syndrome | 16 | 2011 | 141 | 3.130 |
Why?
|
| Drug Resistance | 24 | 2021 | 256 | 3.020 |
Why?
|
| Insulin Resistance | 18 | 2020 | 377 | 2.870 |
Why?
|
| Cardiovascular System | 10 | 2021 | 71 | 2.860 |
Why?
|
| Health Promotion | 11 | 2009 | 160 | 2.800 |
Why?
|
| Acute Coronary Syndrome | 16 | 2022 | 45 | 2.800 |
Why?
|
| Blood Glucose | 41 | 2023 | 873 | 2.800 |
Why?
|
| Benzazepines | 25 | 2018 | 89 | 2.790 |
Why?
|
| Pyrazoles | 7 | 2022 | 153 | 2.780 |
Why?
|
| Propanolamines | 18 | 2010 | 36 | 2.760 |
Why?
|
| Clinical Trials as Topic | 48 | 2023 | 1169 | 2.730 |
Why?
|
| Carbazoles | 18 | 2010 | 51 | 2.720 |
Why?
|
| Denervation | 10 | 2022 | 34 | 2.710 |
Why?
|
| Diabetes Mellitus, Type 1 | 17 | 2023 | 567 | 2.670 |
Why?
|
| Aldosterone | 9 | 2022 | 65 | 2.650 |
Why?
|
| Renal Insufficiency | 15 | 2023 | 114 | 2.640 |
Why?
|
| Quinolines | 5 | 2022 | 95 | 2.630 |
Why?
|
| Electric Stimulation Therapy | 8 | 2017 | 51 | 2.570 |
Why?
|
| Spironolactone | 11 | 2022 | 23 | 2.500 |
Why?
|
| Catheter Ablation | 8 | 2017 | 233 | 2.490 |
Why?
|
| Coronary Artery Disease | 14 | 2018 | 350 | 2.460 |
Why?
|
| Metformin | 8 | 2022 | 128 | 2.440 |
Why?
|
| Losartan | 13 | 2018 | 42 | 2.340 |
Why?
|
| Polymers | 9 | 2020 | 202 | 2.330 |
Why?
|
| Chlorthalidone | 8 | 2018 | 25 | 2.300 |
Why?
|
| Uracil | 16 | 2021 | 72 | 2.270 |
Why?
|
| Global Health | 16 | 2012 | 193 | 2.270 |
Why?
|
| United States | 94 | 2023 | 6665 | 2.240 |
Why?
|
| Drug Combinations | 24 | 2022 | 224 | 2.230 |
Why?
|
| Mass Screening | 18 | 2017 | 617 | 2.190 |
Why?
|
| Cardiology | 11 | 2021 | 123 | 2.180 |
Why?
|
| Myocardial Infarction | 23 | 2023 | 375 | 2.080 |
Why?
|
| Imidazoles | 13 | 2018 | 162 | 2.070 |
Why?
|
| Benzoates | 12 | 2012 | 44 | 2.070 |
Why?
|
| Chronic Disease | 42 | 2014 | 970 | 2.010 |
Why?
|
| Atherosclerosis | 5 | 2023 | 243 | 1.960 |
Why?
|
| Risk Assessment | 48 | 2021 | 2261 | 1.930 |
Why?
|
| Comorbidity | 33 | 2023 | 943 | 1.920 |
Why?
|
| Adult | 131 | 2024 | 25640 | 1.910 |
Why?
|
| Glucose | 14 | 2023 | 638 | 1.910 |
Why?
|
| Benzopyrans | 8 | 2013 | 20 | 1.880 |
Why?
|
| Baroreflex | 10 | 2022 | 17 | 1.870 |
Why?
|
| Thiazolidinediones | 9 | 2013 | 82 | 1.860 |
Why?
|
| Ethanolamines | 8 | 2013 | 32 | 1.860 |
Why?
|
| Pressoreceptors | 11 | 2023 | 22 | 1.800 |
Why?
|
| Fumarates | 7 | 2015 | 26 | 1.780 |
Why?
|
| Amides | 7 | 2015 | 60 | 1.760 |
Why?
|
| Metoprolol | 15 | 2013 | 30 | 1.760 |
Why?
|
| Risk Reduction Behavior | 6 | 2021 | 98 | 1.740 |
Why?
|
| Obesity | 21 | 2023 | 963 | 1.710 |
Why?
|
| Ramipril | 10 | 2013 | 12 | 1.700 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2016 | 73 | 1.690 |
Why?
|
| Endothelins | 9 | 2022 | 35 | 1.690 |
Why?
|
| Goals | 6 | 2018 | 67 | 1.680 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 8 | 2021 | 43 | 1.670 |
Why?
|
| Hypotension | 3 | 2024 | 70 | 1.670 |
Why?
|
| Weight Loss | 7 | 2021 | 229 | 1.660 |
Why?
|
| Renin | 13 | 2017 | 79 | 1.660 |
Why?
|
| Endothelin Receptor Antagonists | 8 | 2022 | 19 | 1.580 |
Why?
|
| Foundations | 10 | 2011 | 25 | 1.570 |
Why?
|
| Acute Kidney Injury | 6 | 2020 | 295 | 1.520 |
Why?
|
| Prospective Studies | 52 | 2022 | 4210 | 1.500 |
Why?
|
| Verapamil | 14 | 2008 | 48 | 1.490 |
Why?
|
| Sodium | 13 | 2023 | 341 | 1.490 |
Why?
|
| Incidence | 35 | 2023 | 1576 | 1.470 |
Why?
|
| Angiotensinogen | 3 | 2024 | 8 | 1.420 |
Why?
|
| Time Factors | 37 | 2021 | 5209 | 1.420 |
Why?
|
| Exercise | 6 | 2021 | 315 | 1.420 |
Why?
|
| Hypercholesterolemia | 5 | 2017 | 161 | 1.400 |
Why?
|
| Coronary Vasospasm | 4 | 2018 | 12 | 1.390 |
Why?
|
| Glucosides | 8 | 2020 | 20 | 1.390 |
Why?
|
| Silicates | 4 | 2016 | 8 | 1.380 |
Why?
|
| Prognosis | 43 | 2021 | 3674 | 1.330 |
Why?
|
| Follow-Up Studies | 48 | 2022 | 3636 | 1.320 |
Why?
|
| Masked Hypertension | 3 | 2018 | 4 | 1.310 |
Why?
|
| Life Style | 18 | 2021 | 189 | 1.280 |
Why?
|
| Valine | 7 | 2012 | 69 | 1.270 |
Why?
|
| Prevalence | 30 | 2018 | 1239 | 1.250 |
Why?
|
| Thiophenes | 6 | 2015 | 48 | 1.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 9 | 2021 | 14 | 1.220 |
Why?
|
| Severity of Illness Index | 28 | 2018 | 1801 | 1.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 5 | 2020 | 9 | 1.180 |
Why?
|
| Nephrology | 7 | 2021 | 45 | 1.170 |
Why?
|
| Perindopril | 4 | 2015 | 4 | 1.170 |
Why?
|
| Exercise Test | 2 | 2021 | 164 | 1.140 |
Why?
|
| Biphenyl Compounds | 10 | 2022 | 68 | 1.130 |
Why?
|
| Hypokalemia | 7 | 2020 | 29 | 1.130 |
Why?
|
| Biomarkers | 25 | 2022 | 1718 | 1.120 |
Why?
|
| Primary Prevention | 7 | 2009 | 85 | 1.110 |
Why?
|
| Vasodilator Agents | 9 | 2010 | 152 | 1.100 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2018 | 7 | 1.100 |
Why?
|
| Renal Circulation | 14 | 2015 | 61 | 1.060 |
Why?
|
| Lisinopril | 10 | 2013 | 14 | 1.050 |
Why?
|
| Dose-Response Relationship, Drug | 32 | 2018 | 1961 | 1.040 |
Why?
|
| Body Mass Index | 13 | 2021 | 770 | 1.040 |
Why?
|
| Heart Rate | 15 | 2020 | 492 | 1.030 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 581 | 1.030 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2024 | 12 | 1.020 |
Why?
|
| American Heart Association | 8 | 2023 | 92 | 1.020 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2017 | 219 | 1.020 |
Why?
|
| Risk | 17 | 2020 | 674 | 1.010 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 2 | 2015 | 9 | 1.000 |
Why?
|
| Atenolol | 8 | 2010 | 34 | 1.000 |
Why?
|
| Diet, Sodium-Restricted | 7 | 2017 | 14 | 0.990 |
Why?
|
| Primary Health Care | 9 | 2022 | 339 | 0.980 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 11 | 0.980 |
Why?
|
| Hyperglycemia | 7 | 2018 | 176 | 0.980 |
Why?
|
| Circadian Rhythm | 9 | 2022 | 303 | 0.980 |
Why?
|
| Hemodynamics | 19 | 2013 | 710 | 0.980 |
Why?
|
| Evidence-Based Medicine | 14 | 2017 | 429 | 0.970 |
Why?
|
| Acidosis, Lactic | 2 | 2016 | 12 | 0.970 |
Why?
|
| Systole | 20 | 2017 | 129 | 0.970 |
Why?
|
| Physician's Role | 4 | 2020 | 179 | 0.960 |
Why?
|
| Indoles | 12 | 2009 | 318 | 0.950 |
Why?
|
| Patient Education as Topic | 9 | 2010 | 351 | 0.940 |
Why?
|
| Hyperinsulinism | 4 | 2007 | 51 | 0.910 |
Why?
|
| Cardiovascular Agents | 4 | 2017 | 56 | 0.890 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2022 | 6 | 0.890 |
Why?
|
| Animals | 60 | 2022 | 26581 | 0.870 |
Why?
|
| Stroke | 22 | 2023 | 965 | 0.870 |
Why?
|
| Cohort Studies | 27 | 2023 | 2767 | 0.860 |
Why?
|
| Nutrition Surveys | 6 | 2023 | 114 | 0.850 |
Why?
|
| Disease Management | 13 | 2020 | 327 | 0.840 |
Why?
|
| Valsartan | 10 | 2022 | 20 | 0.830 |
Why?
|
| Endothelium, Vascular | 7 | 2010 | 435 | 0.830 |
Why?
|
| Weight Gain | 2 | 2022 | 123 | 0.820 |
Why?
|
| Midodrine | 2 | 2018 | 5 | 0.800 |
Why?
|
| Sleep | 3 | 2020 | 444 | 0.800 |
Why?
|
| Delayed-Action Preparations | 7 | 2010 | 116 | 0.790 |
Why?
|
| Age Factors | 21 | 2021 | 1849 | 0.780 |
Why?
|
| Research Design | 14 | 2019 | 594 | 0.780 |
Why?
|
| Oleanolic Acid | 6 | 2018 | 13 | 0.770 |
Why?
|
| Retinal Diseases | 1 | 2022 | 90 | 0.760 |
Why?
|
| Patient Selection | 11 | 2020 | 685 | 0.760 |
Why?
|
| Drug Administration Schedule | 17 | 2016 | 916 | 0.760 |
Why?
|
| Capparis | 1 | 2020 | 2 | 0.750 |
Why?
|
| International Cooperation | 3 | 2009 | 127 | 0.740 |
Why?
|
| Early Diagnosis | 11 | 2011 | 131 | 0.740 |
Why?
|
| Proportional Hazards Models | 24 | 2021 | 857 | 0.730 |
Why?
|
| Insulin | 12 | 2023 | 1160 | 0.730 |
Why?
|
| Uric Acid | 3 | 2021 | 139 | 0.730 |
Why?
|
| Adolescent | 29 | 2023 | 8979 | 0.720 |
Why?
|
| Kidney Transplantation | 6 | 2020 | 849 | 0.710 |
Why?
|
| Hyperuricemia | 3 | 2018 | 27 | 0.710 |
Why?
|
| Nebivolol | 9 | 2015 | 9 | 0.710 |
Why?
|
| Polystyrenes | 2 | 2016 | 9 | 0.710 |
Why?
|
| Drug Substitution | 2 | 2016 | 25 | 0.710 |
Why?
|
| Heart Failure, Systolic | 2 | 2016 | 7 | 0.700 |
Why?
|
| Program Evaluation | 7 | 2013 | 297 | 0.700 |
Why?
|
| Symporters | 2 | 2020 | 107 | 0.700 |
Why?
|
| Carotid Sinus | 4 | 2014 | 24 | 0.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2012 | 378 | 0.690 |
Why?
|
| Vascular Diseases | 4 | 2011 | 119 | 0.690 |
Why?
|
| Aged, 80 and over | 33 | 2023 | 6501 | 0.690 |
Why?
|
| Coronary Disease | 5 | 2014 | 261 | 0.680 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 47 | 0.680 |
Why?
|
| Dihydropyridines | 5 | 2013 | 11 | 0.680 |
Why?
|
| Panic Disorder | 1 | 2018 | 22 | 0.680 |
Why?
|
| Multicenter Studies as Topic | 10 | 2020 | 159 | 0.660 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 58 | 0.660 |
Why?
|
| Olmesartan Medoxomil | 1 | 2018 | 1 | 0.650 |
Why?
|
| Indapamide | 3 | 2013 | 3 | 0.650 |
Why?
|
| RNA Interference | 3 | 2024 | 369 | 0.650 |
Why?
|
| Kidney Function Tests | 9 | 2020 | 123 | 0.650 |
Why?
|
| Annual Reports as Topic | 4 | 2011 | 5 | 0.640 |
Why?
|
| Cross-Over Studies | 8 | 2020 | 399 | 0.640 |
Why?
|
| Benzhydryl Compounds | 5 | 2020 | 48 | 0.640 |
Why?
|
| Predictive Value of Tests | 17 | 2021 | 1673 | 0.640 |
Why?
|
| Hospitalization | 21 | 2021 | 848 | 0.630 |
Why?
|
| Diltiazem | 10 | 2012 | 17 | 0.620 |
Why?
|
| Health Behavior | 1 | 2019 | 183 | 0.620 |
Why?
|
| Aging | 4 | 2017 | 691 | 0.620 |
Why?
|
| Leuprolide | 1 | 2017 | 30 | 0.610 |
Why?
|
| Thiazoles | 4 | 2013 | 131 | 0.610 |
Why?
|
| Pyrimidines | 4 | 2020 | 370 | 0.600 |
Why?
|
| Hypolipidemic Agents | 4 | 2011 | 102 | 0.600 |
Why?
|
| Consensus | 6 | 2022 | 335 | 0.600 |
Why?
|
| Menstrual Cycle | 1 | 2017 | 55 | 0.600 |
Why?
|
| Periodicals as Topic | 3 | 2014 | 167 | 0.600 |
Why?
|
| Hypertension, Renovascular | 2 | 2009 | 14 | 0.590 |
Why?
|
| Glycation End Products, Advanced | 2 | 2008 | 13 | 0.590 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 103 | 0.590 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2017 | 318 | 0.590 |
Why?
|
| Sodium, Dietary | 5 | 2014 | 13 | 0.580 |
Why?
|
| Albumins | 4 | 2022 | 133 | 0.580 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 8 | 0.570 |
Why?
|
| Awareness | 5 | 2010 | 93 | 0.570 |
Why?
|
| Drugs, Generic | 1 | 2016 | 21 | 0.570 |
Why?
|
| Urinalysis | 2 | 2007 | 33 | 0.570 |
Why?
|
| Colonic Diseases | 4 | 2016 | 65 | 0.560 |
Why?
|
| Phenylpropionates | 3 | 2010 | 10 | 0.560 |
Why?
|
| Diabetic Neuropathies | 2 | 2022 | 40 | 0.550 |
Why?
|
| Doxazosin | 1 | 2015 | 2 | 0.550 |
Why?
|
| Bisoprolol | 1 | 2015 | 3 | 0.550 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2015 | 8 | 0.550 |
Why?
|
| Life Expectancy | 1 | 2016 | 86 | 0.540 |
Why?
|
| Cyclosporine | 1 | 2016 | 234 | 0.540 |
Why?
|
| Parathyroid Hormone | 4 | 2009 | 218 | 0.540 |
Why?
|
| Young Adult | 16 | 2023 | 5974 | 0.530 |
Why?
|
| Arteries | 2 | 2007 | 176 | 0.530 |
Why?
|
| Health Care Reform | 4 | 2016 | 90 | 0.530 |
Why?
|
| Colectomy | 4 | 2016 | 167 | 0.530 |
Why?
|
| Endothelin A Receptor Antagonists | 4 | 2019 | 11 | 0.520 |
Why?
|
| Attitude to Health | 2 | 2008 | 220 | 0.520 |
Why?
|
| Enalapril | 5 | 2005 | 18 | 0.520 |
Why?
|
| Diastole | 11 | 2012 | 144 | 0.510 |
Why?
|
| Early Termination of Clinical Trials | 4 | 2016 | 20 | 0.510 |
Why?
|
| Hypotension, Orthostatic | 2 | 2014 | 5 | 0.510 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2023 | 48 | 0.510 |
Why?
|
| Combined Modality Therapy | 9 | 2018 | 1685 | 0.500 |
Why?
|
| Dyslipidemias | 4 | 2011 | 109 | 0.500 |
Why?
|
| Glomerular Mesangium | 5 | 1994 | 23 | 0.490 |
Why?
|
| Administration, Oral | 9 | 2019 | 684 | 0.490 |
Why?
|
| Gliclazide | 1 | 2013 | 1 | 0.490 |
Why?
|
| Diabetic Retinopathy | 2 | 2022 | 87 | 0.490 |
Why?
|
| Heart Diseases | 2 | 2008 | 290 | 0.480 |
Why?
|
| Patient Compliance | 8 | 2014 | 227 | 0.480 |
Why?
|
| Vasodilation | 3 | 2009 | 96 | 0.480 |
Why?
|
| Patient Admission | 1 | 2014 | 112 | 0.480 |
Why?
|
| Europe | 5 | 2019 | 309 | 0.480 |
Why?
|
| Emergency Medical Services | 4 | 2016 | 209 | 0.470 |
Why?
|
| Pilot Projects | 8 | 2020 | 839 | 0.470 |
Why?
|
| Catheterization | 1 | 2015 | 232 | 0.470 |
Why?
|
| Population Surveillance | 5 | 2010 | 219 | 0.470 |
Why?
|
| Gout Suppressants | 1 | 2013 | 36 | 0.470 |
Why?
|
| Homeostasis | 8 | 2015 | 409 | 0.470 |
Why?
|
| Cause of Death | 10 | 2020 | 277 | 0.460 |
Why?
|
| Vascular Calcification | 1 | 2014 | 39 | 0.460 |
Why?
|
| Prediabetic State | 2 | 2016 | 39 | 0.460 |
Why?
|
| Body Weight | 7 | 2014 | 459 | 0.460 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2010 | 80 | 0.460 |
Why?
|
| Survival Rate | 15 | 2021 | 1860 | 0.460 |
Why?
|
| Cross-Sectional Studies | 14 | 2012 | 1621 | 0.450 |
Why?
|
| Gout | 1 | 2013 | 76 | 0.450 |
Why?
|
| Compliance | 3 | 2007 | 23 | 0.450 |
Why?
|
| Medication Adherence | 6 | 2015 | 129 | 0.440 |
Why?
|
| Inflammation | 4 | 2022 | 920 | 0.440 |
Why?
|
| Analysis of Variance | 10 | 2018 | 912 | 0.440 |
Why?
|
| Uremia | 1 | 2012 | 15 | 0.440 |
Why?
|
| Nitric Oxide | 3 | 2010 | 278 | 0.430 |
Why?
|
| Reference Values | 10 | 2018 | 674 | 0.430 |
Why?
|
| Health Priorities | 2 | 2011 | 23 | 0.420 |
Why?
|
| Multivariate Analysis | 14 | 2016 | 999 | 0.420 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2022 | 56 | 0.420 |
Why?
|
| Contrast Media | 6 | 1999 | 1077 | 0.420 |
Why?
|
| Fatty Liver | 2 | 2023 | 124 | 0.420 |
Why?
|
| United Nations | 1 | 2011 | 2 | 0.420 |
Why?
|
| Morbidity | 7 | 2014 | 148 | 0.410 |
Why?
|
| Cardiotonic Agents | 3 | 2008 | 87 | 0.410 |
Why?
|
| Thiazides | 4 | 2019 | 19 | 0.410 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2012 | 508 | 0.410 |
Why?
|
| Aorta | 1 | 2013 | 280 | 0.410 |
Why?
|
| Health Education | 2 | 2009 | 100 | 0.410 |
Why?
|
| Sodium Chloride, Dietary | 4 | 2020 | 11 | 0.400 |
Why?
|
| Simvastatin | 1 | 2011 | 106 | 0.400 |
Why?
|
| Sleep Wake Disorders | 1 | 2012 | 115 | 0.390 |
Why?
|
| Fenofibrate | 1 | 2011 | 21 | 0.390 |
Why?
|
| Serum Albumin | 2 | 2009 | 130 | 0.390 |
Why?
|
| Glucagon-Like Peptides | 3 | 2023 | 8 | 0.390 |
Why?
|
| Calcium | 4 | 2009 | 1156 | 0.390 |
Why?
|
| Leadership | 2 | 2011 | 134 | 0.380 |
Why?
|
| Angiotensin II | 5 | 2004 | 94 | 0.380 |
Why?
|
| Diet | 5 | 2023 | 443 | 0.380 |
Why?
|
| Diuresis | 3 | 2019 | 29 | 0.380 |
Why?
|
| Delivery of Health Care | 4 | 2014 | 426 | 0.380 |
Why?
|
| Endothelium | 2 | 2007 | 59 | 0.370 |
Why?
|
| Glucose Intolerance | 2 | 2010 | 96 | 0.370 |
Why?
|
| Natriuresis | 2 | 2007 | 30 | 0.370 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 28 | 0.360 |
Why?
|
| Anti-Obesity Agents | 2 | 2016 | 14 | 0.360 |
Why?
|
| Overweight | 2 | 2016 | 118 | 0.360 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2010 | 92 | 0.360 |
Why?
|
| Pheochromocytoma | 1 | 2010 | 49 | 0.360 |
Why?
|
| Retrospective Studies | 20 | 2023 | 8475 | 0.350 |
Why?
|
| Nephritis | 2 | 2022 | 20 | 0.350 |
Why?
|
| Receptors, Angiotensin | 3 | 2005 | 15 | 0.350 |
Why?
|
| Forecasting | 4 | 2016 | 304 | 0.340 |
Why?
|
| Oxidative Stress | 1 | 2011 | 447 | 0.330 |
Why?
|
| Anemia | 4 | 2020 | 128 | 0.330 |
Why?
|
| Potassium, Dietary | 3 | 2020 | 3 | 0.330 |
Why?
|
| Blood Vessels | 2 | 2005 | 94 | 0.330 |
Why?
|
| Patient Care Planning | 2 | 2012 | 81 | 0.320 |
Why?
|
| African Americans | 5 | 2002 | 10 | 0.320 |
Why?
|
| Stroke Volume | 4 | 2020 | 456 | 0.320 |
Why?
|
| Nifedipine | 4 | 1998 | 28 | 0.320 |
Why?
|
| Pulse | 1 | 2007 | 18 | 0.310 |
Why?
|
| Diatrizoate Meglumine | 4 | 1999 | 24 | 0.310 |
Why?
|
| Manipulation, Chiropractic | 1 | 2007 | 2 | 0.300 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 48 | 0.300 |
Why?
|
| Cervical Atlas | 1 | 2007 | 4 | 0.300 |
Why?
|
| Cystatin C | 3 | 2018 | 31 | 0.300 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 190 | 0.300 |
Why?
|
| Protein Kinase C | 2 | 2007 | 270 | 0.300 |
Why?
|
| Congresses as Topic | 4 | 2014 | 116 | 0.300 |
Why?
|
| Health Care Costs | 6 | 2016 | 237 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2008 | 243 | 0.290 |
Why?
|
| Nitric Oxide Synthase | 1 | 2007 | 125 | 0.290 |
Why?
|
| Pre-Eclampsia | 1 | 2010 | 246 | 0.290 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 70 | 0.290 |
Why?
|
| Body Size | 3 | 2013 | 91 | 0.290 |
Why?
|
| Referral and Consultation | 3 | 2011 | 326 | 0.290 |
Why?
|
| Catheters | 3 | 2022 | 74 | 0.290 |
Why?
|
| Chi-Square Distribution | 6 | 2015 | 364 | 0.290 |
Why?
|
| Japan | 5 | 2020 | 307 | 0.290 |
Why?
|
| Self Care | 2 | 2007 | 164 | 0.280 |
Why?
|
| Arginine Vasopressin | 3 | 1997 | 47 | 0.280 |
Why?
|
| Cholesterol | 3 | 2010 | 356 | 0.280 |
Why?
|
| Sex Factors | 12 | 2021 | 1054 | 0.280 |
Why?
|
| Dipeptides | 4 | 2013 | 46 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2013 | 860 | 0.280 |
Why?
|
| Advisory Committees | 3 | 2011 | 90 | 0.270 |
Why?
|
| Acrylates | 1 | 2005 | 19 | 0.270 |
Why?
|
| Endpoint Determination | 3 | 2021 | 60 | 0.270 |
Why?
|
| Survival Analysis | 8 | 2019 | 1538 | 0.270 |
Why?
|
| Least-Squares Analysis | 2 | 2015 | 48 | 0.270 |
Why?
|
| Drug Evaluation | 3 | 2008 | 141 | 0.270 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 35 | 0.270 |
Why?
|
| Vascular Resistance | 4 | 2010 | 102 | 0.260 |
Why?
|
| Precision Medicine | 3 | 2018 | 395 | 0.260 |
Why?
|
| Sitagliptin Phosphate | 2 | 2016 | 3 | 0.260 |
Why?
|
| Mineralocorticoids | 2 | 2022 | 10 | 0.260 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 370 | 0.260 |
Why?
|
| Education | 2 | 2018 | 58 | 0.260 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 172 | 0.260 |
Why?
|
| Electrodes, Implanted | 3 | 2016 | 171 | 0.260 |
Why?
|
| Atrial Fibrillation | 2 | 2021 | 288 | 0.260 |
Why?
|
| Regression Analysis | 3 | 2016 | 596 | 0.250 |
Why?
|
| Random Allocation | 3 | 2020 | 332 | 0.250 |
Why?
|
| Peptide Fragments | 3 | 2020 | 460 | 0.250 |
Why?
|
| Dogs | 9 | 2012 | 685 | 0.250 |
Why?
|
| United Kingdom | 3 | 2013 | 164 | 0.250 |
Why?
|
| Kidney Glomerulus | 5 | 1999 | 123 | 0.250 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 162 | 0.250 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 639 | 0.250 |
Why?
|
| Cytokines | 1 | 2008 | 776 | 0.250 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2024 | 9 | 0.240 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 40 | 0.240 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 228 | 0.240 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 4 | 2000 | 38 | 0.240 |
Why?
|
| Single-Blind Method | 5 | 2022 | 153 | 0.240 |
Why?
|
| Clonidine | 4 | 1996 | 37 | 0.240 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2004 | 24 | 0.230 |
Why?
|
| Injections, Subcutaneous | 1 | 2023 | 117 | 0.230 |
Why?
|
| China | 1 | 2024 | 228 | 0.230 |
Why?
|
| Maleimides | 3 | 2009 | 29 | 0.230 |
Why?
|
| Myocardial Revascularization | 4 | 2017 | 31 | 0.230 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 57 | 0.230 |
Why?
|
| Soft Tissue Infections | 1 | 2023 | 26 | 0.230 |
Why?
|
| Meta-Analysis as Topic | 2 | 2013 | 87 | 0.230 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2017 | 159 | 0.230 |
Why?
|
| Phosphates | 1 | 2023 | 160 | 0.220 |
Why?
|
| Lactones | 1 | 2002 | 28 | 0.220 |
Why?
|
| Aminobutyrates | 1 | 2022 | 13 | 0.220 |
Why?
|
| Aortic Diseases | 4 | 2010 | 100 | 0.220 |
Why?
|
| Child | 5 | 2022 | 6926 | 0.220 |
Why?
|
| Triglycerides | 2 | 2009 | 232 | 0.220 |
Why?
|
| Neprilysin | 1 | 2022 | 42 | 0.220 |
Why?
|
| Organic Anion Transporters | 1 | 2022 | 27 | 0.220 |
Why?
|
| Physicians, Family | 1 | 2002 | 40 | 0.220 |
Why?
|
| Aorta, Thoracic | 4 | 2010 | 165 | 0.220 |
Why?
|
| Pharmacokinetics | 2 | 2000 | 12 | 0.210 |
Why?
|
| Liraglutide | 1 | 2021 | 5 | 0.210 |
Why?
|
| Symptom Flare Up | 1 | 2021 | 11 | 0.210 |
Why?
|
| Publishing | 1 | 2023 | 90 | 0.210 |
Why?
|
| Pregnancy | 4 | 2022 | 2893 | 0.210 |
Why?
|
| Quality of Life | 6 | 2023 | 1583 | 0.210 |
Why?
|
| Adaptation, Physiological | 2 | 1994 | 306 | 0.210 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2021 | 6 | 0.210 |
Why?
|
| Cost of Illness | 3 | 2011 | 150 | 0.200 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 19 | 0.200 |
Why?
|
| Lipocalin-2 | 2 | 2018 | 38 | 0.200 |
Why?
|
| Placebos | 6 | 2020 | 218 | 0.200 |
Why?
|
| Erythrocyte Indices | 1 | 2021 | 10 | 0.200 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1993 | 190 | 0.200 |
Why?
|
| Guanylyl Cyclase C Agonists | 1 | 2020 | 1 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2002 | 138 | 0.200 |
Why?
|
| Algorithms | 6 | 2010 | 1830 | 0.200 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 30 | 0.190 |
Why?
|
| Ankle Brachial Index | 1 | 2020 | 27 | 0.190 |
Why?
|
| Troponin I | 2 | 2020 | 27 | 0.190 |
Why?
|
| Osteoporosis | 1 | 2022 | 121 | 0.190 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 2 | 1997 | 29 | 0.190 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 119 | 0.190 |
Why?
|
| Education, Medical, Continuing | 2 | 2013 | 107 | 0.190 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 26 | 0.190 |
Why?
|
| Fractures, Bone | 1 | 2022 | 131 | 0.190 |
Why?
|
| Renal Artery Obstruction | 2 | 2011 | 39 | 0.190 |
Why?
|
| Contraindications, Drug | 1 | 2020 | 5 | 0.190 |
Why?
|
| Colonic Polyps | 1 | 2021 | 126 | 0.190 |
Why?
|
| Heart | 1 | 2023 | 539 | 0.190 |
Why?
|
| Guideline Adherence | 3 | 2008 | 223 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2021 | 255 | 0.180 |
Why?
|
| Pharmacology, Clinical | 1 | 2000 | 9 | 0.180 |
Why?
|
| Health Surveys | 3 | 2009 | 239 | 0.180 |
Why?
|
| RNA | 1 | 2024 | 560 | 0.180 |
Why?
|
| Community Health Services | 3 | 2010 | 80 | 0.180 |
Why?
|
| Fear | 1 | 2020 | 78 | 0.180 |
Why?
|
| Thoracic Surgery | 2 | 2010 | 43 | 0.180 |
Why?
|
| Smoking | 5 | 2013 | 609 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 176 | 0.180 |
Why?
|
| Lipids | 4 | 2011 | 269 | 0.180 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 9 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2011 | 199 | 0.170 |
Why?
|
| Registries | 2 | 2017 | 702 | 0.170 |
Why?
|
| Myocardial Ischemia | 2 | 2018 | 162 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2016 | 312 | 0.170 |
Why?
|
| Evaluation Studies as Topic | 3 | 2010 | 274 | 0.170 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1999 | 34 | 0.170 |
Why?
|
| Vascular Surgical Procedures | 2 | 2010 | 148 | 0.170 |
Why?
|
| Feeding Behavior | 3 | 2011 | 324 | 0.170 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2018 | 3 | 0.170 |
Why?
|
| Hospitals | 1 | 2022 | 294 | 0.170 |
Why?
|
| Alcohol Drinking | 3 | 2013 | 266 | 0.170 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2010 | 87 | 0.170 |
Why?
|
| Prehypertension | 2 | 2015 | 3 | 0.170 |
Why?
|
| Organic Chemicals | 1 | 2018 | 33 | 0.170 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 2009 | 70 | 0.170 |
Why?
|
| Proteomics | 1 | 2020 | 212 | 0.170 |
Why?
|
| Kidney Tubules | 2 | 2007 | 94 | 0.160 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 222 | 0.160 |
Why?
|
| Health Planning Guidelines | 2 | 2008 | 24 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 163 | 0.160 |
Why?
|
| Hypoglycemia | 2 | 2017 | 107 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2022 | 428 | 0.160 |
Why?
|
| Intention to Treat Analysis | 3 | 2014 | 72 | 0.160 |
Why?
|
| Phosphorus | 2 | 2009 | 118 | 0.160 |
Why?
|
| Fertility Agents, Female | 1 | 2017 | 4 | 0.160 |
Why?
|
| Logistic Models | 6 | 2015 | 1185 | 0.160 |
Why?
|
| Lithium | 3 | 1983 | 59 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 148 | 0.150 |
Why?
|
| Nephritis, Interstitial | 4 | 1994 | 47 | 0.150 |
Why?
|
| Angina, Unstable | 2 | 2015 | 8 | 0.150 |
Why?
|
| Direct Service Costs | 1 | 1997 | 3 | 0.150 |
Why?
|
| Osteoarthritis | 2 | 2011 | 73 | 0.150 |
Why?
|
| Edema | 2 | 2015 | 71 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 2 | 2000 | 92 | 0.150 |
Why?
|
| Massachusetts | 4 | 2016 | 33 | 0.150 |
Why?
|
| Population | 1 | 1997 | 35 | 0.150 |
Why?
|
| Niacinamide | 2 | 2014 | 116 | 0.150 |
Why?
|
| Coronary Vessels | 2 | 2015 | 177 | 0.150 |
Why?
|
| Glucose Tolerance Test | 2 | 2008 | 228 | 0.150 |
Why?
|
| Phenylurea Compounds | 2 | 2014 | 113 | 0.150 |
Why?
|
| Caffeine | 1 | 2017 | 81 | 0.150 |
Why?
|
| Zirconium | 1 | 2016 | 2 | 0.150 |
Why?
|
| Sodium Chloride | 1 | 1996 | 86 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 740 | 0.140 |
Why?
|
| Socioeconomic Factors | 6 | 2016 | 567 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2009 | 812 | 0.140 |
Why?
|
| Reagent Strips | 2 | 2007 | 6 | 0.140 |
Why?
|
| Isradipine | 1 | 1996 | 1 | 0.140 |
Why?
|
| Dementia, Vascular | 1 | 2016 | 7 | 0.140 |
Why?
|
| Attitude of Health Personnel | 4 | 2009 | 636 | 0.140 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 469 | 0.140 |
Why?
|
| Bupropion | 1 | 2016 | 21 | 0.140 |
Why?
|
| Allopurinol | 2 | 2013 | 80 | 0.140 |
Why?
|
| Videoconferencing | 2 | 2013 | 16 | 0.140 |
Why?
|
| Decision Trees | 3 | 2004 | 63 | 0.140 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 104 | 0.140 |
Why?
|
| Genotype | 5 | 2016 | 1850 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2014 | 285 | 0.140 |
Why?
|
| Nephrosclerosis | 2 | 2009 | 7 | 0.140 |
Why?
|
| Postmenopause | 1 | 2016 | 98 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 175 | 0.140 |
Why?
|
| Cooperative Behavior | 3 | 2011 | 174 | 0.130 |
Why?
|
| Insurance, Health | 4 | 2016 | 160 | 0.130 |
Why?
|
| Benchmarking | 2 | 2008 | 78 | 0.130 |
Why?
|
| Diatrizoate | 3 | 1990 | 15 | 0.130 |
Why?
|
| Patient Safety | 2 | 2014 | 212 | 0.130 |
Why?
|
| Fibrosis | 3 | 2023 | 203 | 0.130 |
Why?
|
| Calcium Channels, T-Type | 2 | 2008 | 27 | 0.130 |
Why?
|
| Misoprostol | 1 | 1995 | 15 | 0.130 |
Why?
|
| Ibuprofen | 1 | 1995 | 28 | 0.130 |
Why?
|
| Carotid Artery, Common | 1 | 2014 | 29 | 0.130 |
Why?
|
| Adipocytes | 1 | 2016 | 155 | 0.130 |
Why?
|
| Oxygen | 2 | 1990 | 726 | 0.130 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2015 | 60 | 0.130 |
Why?
|
| Residence Characteristics | 4 | 2011 | 197 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 216 | 0.130 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2014 | 14 | 0.130 |
Why?
|
| Naltrexone | 1 | 2016 | 135 | 0.120 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 56 | 0.120 |
Why?
|
| Endothelin-1 | 2 | 2022 | 41 | 0.120 |
Why?
|
| Fludrocortisone | 1 | 2014 | 3 | 0.120 |
Why?
|
| Contraindications | 2 | 2007 | 72 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.120 |
Why?
|
| Stockings, Compression | 1 | 2014 | 6 | 0.120 |
Why?
|
| Renal Reabsorption | 1 | 2014 | 8 | 0.120 |
Why?
|
| Age Distribution | 4 | 2008 | 204 | 0.120 |
Why?
|
| Erythropoietin | 2 | 2013 | 91 | 0.120 |
Why?
|
| Febuxostat | 1 | 2013 | 20 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 70 | 0.120 |
Why?
|
| Hyperaldosteronism | 1 | 1993 | 13 | 0.120 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 16 | 0.120 |
Why?
|
| Neoplasms | 3 | 2014 | 2897 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 938 | 0.120 |
Why?
|
| Accidental Falls | 1 | 2014 | 50 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2014 | 154 | 0.120 |
Why?
|
| Diabetes, Gestational | 2 | 2011 | 39 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2013 | 70 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2013 | 3241 | 0.120 |
Why?
|
| Erythropoiesis | 1 | 2013 | 52 | 0.120 |
Why?
|
| Mitogens | 1 | 1993 | 64 | 0.120 |
Why?
|
| Linagliptin | 1 | 2013 | 1 | 0.110 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2013 | 2 | 0.110 |
Why?
|
| Biguanides | 1 | 2013 | 7 | 0.110 |
Why?
|
| Adamantane | 1 | 2013 | 8 | 0.110 |
Why?
|
| Latin America | 1 | 2013 | 14 | 0.110 |
Why?
|
| Blood Volume | 2 | 2008 | 51 | 0.110 |
Why?
|
| Program Development | 2 | 2013 | 124 | 0.110 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 40 | 0.110 |
Why?
|
| Meglumine | 1 | 2013 | 39 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2011 | 73 | 0.110 |
Why?
|
| Hydralazine | 1 | 2012 | 20 | 0.110 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 34 | 0.110 |
Why?
|
| Hyperlipidemias | 2 | 2011 | 95 | 0.110 |
Why?
|
| Specialization | 1 | 2013 | 65 | 0.110 |
Why?
|
| Community-Based Participatory Research | 1 | 2013 | 36 | 0.110 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 64 | 0.110 |
Why?
|
| Purines | 1 | 2013 | 91 | 0.110 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2007 | 32 | 0.110 |
Why?
|
| Pyrrolidines | 1 | 2013 | 58 | 0.110 |
Why?
|
| White Coat Hypertension | 1 | 2012 | 1 | 0.110 |
Why?
|
| Propensity Score | 4 | 2016 | 136 | 0.110 |
Why?
|
| Nitriles | 1 | 2013 | 149 | 0.110 |
Why?
|
| Family Practice | 1 | 2013 | 84 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2007 | 451 | 0.110 |
Why?
|
| Pyrazines | 1 | 2013 | 92 | 0.110 |
Why?
|
| Triazoles | 1 | 2013 | 96 | 0.110 |
Why?
|
| Secondary Prevention | 3 | 2019 | 162 | 0.110 |
Why?
|
| Rats | 7 | 2014 | 3990 | 0.110 |
Why?
|
| Electric Power Supplies | 1 | 2012 | 9 | 0.110 |
Why?
|
| Equipment and Supplies | 1 | 2012 | 30 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2009 | 678 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2008 | 173 | 0.110 |
Why?
|
| Cell Line | 2 | 2016 | 2468 | 0.110 |
Why?
|
| Isoprostanes | 1 | 2011 | 4 | 0.110 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2012 | 53 | 0.110 |
Why?
|
| Organizational Objectives | 2 | 2009 | 27 | 0.100 |
Why?
|
| Malondialdehyde | 1 | 2011 | 27 | 0.100 |
Why?
|
| Physical Fitness | 1 | 2012 | 51 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2014 | 236 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 10 | 0.100 |
Why?
|
| Receptors, Endothelin | 1 | 2011 | 13 | 0.100 |
Why?
|
| Adiponectin | 1 | 2011 | 24 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2011 | 1804 | 0.100 |
Why?
|
| Urban Health Services | 1 | 2011 | 45 | 0.100 |
Why?
|
| Lipocalins | 1 | 2011 | 35 | 0.100 |
Why?
|
| Adrenergic alpha-Antagonists | 4 | 2010 | 35 | 0.100 |
Why?
|
| Digitalis Glycosides | 2 | 2008 | 3 | 0.100 |
Why?
|
| Adenoma | 1 | 1993 | 235 | 0.100 |
Why?
|
| Norepinephrine | 2 | 1994 | 167 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 220 | 0.100 |
Why?
|
| Practice Management, Medical | 1 | 2011 | 24 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 407 | 0.100 |
Why?
|
| Nitric Oxide Donors | 1 | 2011 | 12 | 0.100 |
Why?
|
| Argentina | 1 | 2011 | 13 | 0.100 |
Why?
|
| World Health Organization | 1 | 2011 | 103 | 0.100 |
Why?
|
| Peru | 1 | 2011 | 24 | 0.100 |
Why?
|
| Naproxen | 1 | 2011 | 13 | 0.100 |
Why?
|
| Health Policy | 1 | 2013 | 180 | 0.100 |
Why?
|
| Mexico | 1 | 2011 | 67 | 0.100 |
Why?
|
| Guanfacine | 1 | 2010 | 2 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 2705 | 0.100 |
Why?
|
| Research Report | 1 | 2011 | 44 | 0.100 |
Why?
|
| Vagus Nerve | 1 | 2010 | 45 | 0.100 |
Why?
|
| Dopamine | 2 | 1994 | 275 | 0.100 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2010 | 21 | 0.100 |
Why?
|
| Parasympathetic Nervous System | 1 | 2010 | 33 | 0.100 |
Why?
|
| Greece | 2 | 2007 | 19 | 0.100 |
Why?
|
| Food Preferences | 1 | 2010 | 26 | 0.100 |
Why?
|
| Chicago | 2 | 2013 | 1379 | 0.100 |
Why?
|
| Polycythemia | 1 | 1990 | 8 | 0.100 |
Why?
|
| Protein Kinase C beta | 2 | 2007 | 16 | 0.100 |
Why?
|
| General Practitioners | 1 | 2010 | 12 | 0.100 |
Why?
|
| Causality | 3 | 2021 | 81 | 0.100 |
Why?
|
| Monitoring, Physiologic | 4 | 2014 | 268 | 0.090 |
Why?
|
| Heart Ventricles | 2 | 2018 | 760 | 0.090 |
Why?
|
| Theophylline | 1 | 1990 | 34 | 0.090 |
Why?
|
| Mucoproteins | 1 | 1990 | 14 | 0.090 |
Why?
|
| Arteriosclerosis | 1 | 2010 | 113 | 0.090 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 62 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 130 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 339 | 0.090 |
Why?
|
| Malnutrition | 1 | 2010 | 34 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 104 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 355 | 0.090 |
Why?
|
| Hormones | 1 | 2010 | 140 | 0.090 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2009 | 5 | 0.090 |
Why?
|
| Brain Stem | 1 | 2010 | 165 | 0.090 |
Why?
|
| Models, Biological | 3 | 2009 | 1749 | 0.090 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1990 | 24 | 0.090 |
Why?
|
| Mice | 3 | 2013 | 11352 | 0.090 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2009 | 43 | 0.090 |
Why?
|
| Diet, Reducing | 1 | 2009 | 31 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2013 | 375 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2013 | 313 | 0.090 |
Why?
|
| Thrombosis | 1 | 2012 | 296 | 0.090 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2009 | 1 | 0.090 |
Why?
|
| Labetalol | 1 | 2009 | 6 | 0.090 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 187 | 0.090 |
Why?
|
| Opioid-Related Disorders | 2 | 1982 | 161 | 0.090 |
Why?
|
| Hemoglobinometry | 1 | 2009 | 9 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 2357 | 0.090 |
Why?
|
| Pyridoxamine | 1 | 2009 | 2 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2009 | 2 | 0.090 |
Why?
|
| Social Environment | 1 | 2010 | 188 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2016 | 229 | 0.090 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2009 | 8 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2013 | 1019 | 0.090 |
Why?
|
| Marriage | 1 | 2009 | 26 | 0.090 |
Why?
|
| Internal Medicine | 1 | 2013 | 347 | 0.090 |
Why?
|
| Drug Industry | 1 | 2009 | 54 | 0.080 |
Why?
|
| Superoxides | 1 | 2009 | 73 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 169 | 0.080 |
Why?
|
| Cardiac Output | 1 | 2009 | 156 | 0.080 |
Why?
|
| Motor Activity | 1 | 2011 | 327 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2011 | 230 | 0.080 |
Why?
|
| Half-Life | 1 | 2008 | 96 | 0.080 |
Why?
|
| Chronotherapy | 1 | 2008 | 1 | 0.080 |
Why?
|
| Cell Division | 4 | 1994 | 696 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2008 | 16 | 0.080 |
Why?
|
| Receptors, Dopamine | 1 | 1988 | 38 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2009 | 128 | 0.080 |
Why?
|
| Placebo Effect | 2 | 2019 | 31 | 0.080 |
Why?
|
| Drug Tolerance | 1 | 2008 | 63 | 0.080 |
Why?
|
| National Health Programs | 1 | 2007 | 20 | 0.080 |
Why?
|
| Dopamine Agents | 1 | 1988 | 29 | 0.080 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 58 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2008 | 60 | 0.080 |
Why?
|
| Research | 2 | 2008 | 253 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1990 | 0.080 |
Why?
|
| Nephrectomy | 4 | 2000 | 294 | 0.080 |
Why?
|
| Polypharmacy | 1 | 2007 | 15 | 0.080 |
Why?
|
| Age of Onset | 1 | 2008 | 310 | 0.080 |
Why?
|
| Carbohydrate Metabolism | 1 | 2007 | 30 | 0.070 |
Why?
|
| Evidence-Based Practice | 2 | 2020 | 45 | 0.070 |
Why?
|
| Glyburide | 1 | 2006 | 32 | 0.070 |
Why?
|
| Forearm | 1 | 1986 | 32 | 0.070 |
Why?
|
| Propranolol | 1 | 1986 | 45 | 0.070 |
Why?
|
| Chromans | 1 | 2006 | 30 | 0.070 |
Why?
|
| Pain | 3 | 2007 | 391 | 0.070 |
Why?
|
| Statistics as Topic | 3 | 2006 | 238 | 0.070 |
Why?
|
| Mortality | 2 | 2004 | 149 | 0.070 |
Why?
|
| Drug Utilization | 2 | 2003 | 65 | 0.070 |
Why?
|
| Recurrence | 3 | 2018 | 1139 | 0.070 |
Why?
|
| Posture | 1 | 1986 | 125 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 72 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2006 | 66 | 0.070 |
Why?
|
| Alabama | 3 | 2012 | 13 | 0.070 |
Why?
|
| Drug Eruptions | 2 | 1991 | 35 | 0.070 |
Why?
|
| Aspirin | 2 | 2004 | 156 | 0.070 |
Why?
|
| Pediatrics | 1 | 2010 | 344 | 0.070 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 244 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 212 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2006 | 91 | 0.070 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 19 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1982 | 48 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2000 | 1565 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2005 | 34 | 0.070 |
Why?
|
| Eating | 1 | 2006 | 166 | 0.070 |
Why?
|
| Pyrroles | 1 | 2006 | 184 | 0.070 |
Why?
|
| Women's Health Services | 1 | 2005 | 15 | 0.070 |
Why?
|
| Androstenes | 1 | 2005 | 43 | 0.070 |
Why?
|
| Medical Audit | 1 | 2005 | 41 | 0.060 |
Why?
|
| Professional-Patient Relations | 1 | 2005 | 53 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 819 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 37 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 301 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2009 | 2356 | 0.060 |
Why?
|
| Diet, Diabetic | 1 | 2004 | 4 | 0.060 |
Why?
|
| Radiography | 2 | 2014 | 813 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2005 | 165 | 0.060 |
Why?
|
| Diclofenac | 1 | 2004 | 4 | 0.060 |
Why?
|
| Estradiol | 1 | 2005 | 252 | 0.060 |
Why?
|
| Vitamin D | 1 | 2006 | 261 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2011 | 751 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1981 | 0.060 |
Why?
|
| Athetosis | 1 | 1983 | 5 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 37 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 33 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 17 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 2 | 2015 | 121 | 0.060 |
Why?
|
| Celecoxib | 1 | 2004 | 31 | 0.060 |
Why?
|
| Chorea | 1 | 1983 | 13 | 0.060 |
Why?
|
| Transferases | 1 | 2023 | 24 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2001 | 1219 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2005 | 141 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 100 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2023 | 73 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 315 | 0.060 |
Why?
|
| Disopyramide | 1 | 1983 | 1 | 0.060 |
Why?
|
| Physicians | 1 | 2011 | 673 | 0.060 |
Why?
|
| Peritoneal Dialysis | 1 | 2003 | 32 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 271 | 0.060 |
Why?
|
| Cholestasis | 1 | 1983 | 47 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2023 | 45 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 1983 | 75 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 1983 | 134 | 0.050 |
Why?
|
| Energy Intake | 1 | 2002 | 98 | 0.050 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 7 | 0.050 |
Why?
|
| Apoprotein(a) | 1 | 2002 | 3 | 0.050 |
Why?
|
| Orphenadrine | 1 | 1982 | 2 | 0.050 |
Why?
|
| Models, Educational | 2 | 2013 | 50 | 0.050 |
Why?
|
| Pain, Intractable | 1 | 1982 | 11 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2002 | 38 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2002 | 28 | 0.050 |
Why?
|
| Models, Econometric | 1 | 2002 | 14 | 0.050 |
Why?
|
| Aquaporins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Analgesics | 1 | 1983 | 119 | 0.050 |
Why?
|
| Psychophysiologic Disorders | 1 | 1981 | 7 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2021 | 5 | 0.050 |
Why?
|
| Pain Management | 1 | 1983 | 127 | 0.050 |
Why?
|
| Vasopressins | 1 | 2002 | 49 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 191 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 49 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2004 | 300 | 0.050 |
Why?
|
| Markov Chains | 1 | 2002 | 125 | 0.050 |
Why?
|
| Headache | 1 | 1982 | 73 | 0.050 |
Why?
|
| Mibefradil | 1 | 2001 | 4 | 0.050 |
Why?
|
| Vertigo | 1 | 1981 | 42 | 0.050 |
Why?
|
| Polyuria | 1 | 1981 | 8 | 0.050 |
Why?
|
| Calcium Channels, L-Type | 1 | 2001 | 39 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 165 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 297 | 0.050 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2020 | 3 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1204 | 0.050 |
Why?
|
| Pyridines | 1 | 1983 | 309 | 0.050 |
Why?
|
| Bone Density | 1 | 2022 | 209 | 0.050 |
Why?
|
| Haplotypes | 3 | 2009 | 642 | 0.050 |
Why?
|
| Dizziness | 1 | 2020 | 27 | 0.050 |
Why?
|
| Syncope | 1 | 2020 | 34 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 361 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 169 | 0.050 |
Why?
|
| Culture | 1 | 2000 | 53 | 0.050 |
Why?
|
| Constipation | 1 | 2020 | 63 | 0.050 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2020 | 9 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 1999 | 2232 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 334 | 0.050 |
Why?
|
| Galectins | 1 | 2020 | 9 | 0.050 |
Why?
|
| Free Radicals | 2 | 1990 | 73 | 0.050 |
Why?
|
| Galectin 3 | 1 | 2020 | 17 | 0.050 |
Why?
|
| Echocardiography | 2 | 2018 | 911 | 0.050 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 61 | 0.050 |
Why?
|
| Diarrhea | 1 | 2020 | 182 | 0.040 |
Why?
|
| Matched-Pair Analysis | 2 | 2010 | 43 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 480 | 0.040 |
Why?
|
| Felodipine | 1 | 1999 | 2 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 70 | 0.040 |
Why?
|
| Serum Albumin, Human | 1 | 2019 | 6 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2270 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2020 | 144 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 307 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2006 | 3611 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 146 | 0.040 |
Why?
|
| Indians, North American | 1 | 1998 | 48 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 1993 | 2818 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 1998 | 50 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1998 | 62 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1998 | 303 | 0.040 |
Why?
|
| Canada | 2 | 2010 | 204 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 2 | 2008 | 10 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2013 | 217 | 0.040 |
Why?
|
| Hormone Antagonists | 1 | 1997 | 20 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1196 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2011 | 535 | 0.040 |
Why?
|
| Syndrome | 1 | 1997 | 446 | 0.040 |
Why?
|
| Operative Time | 1 | 2016 | 127 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1983 | 1075 | 0.040 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 13 | 0.030 |
Why?
|
| Risk Management | 1 | 2016 | 43 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1983 | 1169 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 78 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 2016 | 116 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2016 | 71 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 406 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 130 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 127 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 1056 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 549 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 54 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 270 | 0.030 |
Why?
|
| Prostaglandins | 1 | 1994 | 43 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 108 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1994 | 39 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 1996 | 457 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 26 | 0.030 |
Why?
|
| Urine | 1 | 2014 | 90 | 0.030 |
Why?
|
| Mitosis | 1 | 1994 | 153 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 23 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 1993 | 43 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 94 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 41 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 312 | 0.030 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2013 | 6 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 121 | 0.030 |
Why?
|
| Indazoles | 1 | 2013 | 68 | 0.030 |
Why?
|
| Furosemide | 1 | 1993 | 33 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2014 | 127 | 0.030 |
Why?
|
| Physical Examination | 1 | 2014 | 149 | 0.030 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2012 | 6 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 55 | 0.030 |
Why?
|
| Capillaries | 1 | 1993 | 91 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 76 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2013 | 46 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 134 | 0.030 |
Why?
|
| Growth Substances | 1 | 1992 | 80 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1992 | 69 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 96 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 2600 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2011 | 47 | 0.030 |
Why?
|
| Microcirculation | 1 | 1992 | 106 | 0.030 |
Why?
|
| Glycosuria | 1 | 2011 | 5 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2013 | 319 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2013 | 556 | 0.030 |
Why?
|
| Tobramycin | 1 | 1991 | 10 | 0.030 |
Why?
|
| Psychotropic Drugs | 2 | 1983 | 75 | 0.030 |
Why?
|
| Ketone Bodies | 1 | 2011 | 17 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1991 | 27 | 0.030 |
Why?
|
| Biological Availability | 1 | 2011 | 92 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2006 | 380 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 187 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1990 | 121 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 225 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1983 | 2261 | 0.020 |
Why?
|
| Patient Preference | 1 | 2011 | 105 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1990 | 29 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2012 | 298 | 0.020 |
Why?
|
| Hematocrit | 1 | 1990 | 68 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2011 | 118 | 0.020 |
Why?
|
| Iothalamic Acid | 1 | 1990 | 11 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 63 | 0.020 |
Why?
|
| Uromodulin | 1 | 1990 | 16 | 0.020 |
Why?
|
| Geriatrics | 1 | 2011 | 61 | 0.020 |
Why?
|
| Teaching | 1 | 2011 | 147 | 0.020 |
Why?
|
| Neurology | 1 | 2011 | 70 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1990 | 34 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 2377 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 408 | 0.020 |
Why?
|
| Sympatholytics | 1 | 1989 | 6 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 476 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2010 | 2207 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2011 | 267 | 0.020 |
Why?
|
| Radio Waves | 2 | 2000 | 17 | 0.020 |
Why?
|
| Receptor, Endothelin A | 1 | 2009 | 22 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 1990 | 75 | 0.020 |
Why?
|
| Patient Participation | 1 | 2011 | 216 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1990 | 273 | 0.020 |
Why?
|
| Telemetry | 2 | 2000 | 38 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 989 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1990 | 206 | 0.020 |
Why?
|
| Xanthine Oxidase | 1 | 2009 | 26 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 478 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 712 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2501 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1990 | 177 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 21 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 539 | 0.020 |
Why?
|
| Fenoldopam | 1 | 1988 | 4 | 0.020 |
Why?
|
| Finland | 1 | 2008 | 29 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 102 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 325 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1992 | 374 | 0.020 |
Why?
|
| Receptors, Purinergic | 1 | 1987 | 7 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1994 | 1376 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 261 | 0.020 |
Why?
|
| Bipolar Disorder | 2 | 1981 | 377 | 0.020 |
Why?
|
| Bronchial Spasm | 1 | 2007 | 16 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2011 | 544 | 0.020 |
Why?
|
| Heart Block | 1 | 2007 | 32 | 0.020 |
Why?
|
| Bradycardia | 1 | 2007 | 39 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 105 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 592 | 0.020 |
Why?
|
| Calcifediol | 1 | 2006 | 21 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 179 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 67 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 319 | 0.020 |
Why?
|
| Fatigue | 1 | 2007 | 174 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 1127 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 151 | 0.020 |
Why?
|
| Shear Strength | 1 | 2006 | 19 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2006 | 37 | 0.020 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Calcitriol | 1 | 2006 | 174 | 0.020 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2005 | 15 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1985 | 34 | 0.020 |
Why?
|
| Adenosine | 1 | 1987 | 225 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2006 | 181 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1985 | 93 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 152 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1989 | 746 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 1983 | 8 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 473 | 0.010 |
Why?
|
| Carbamazepine | 1 | 1983 | 10 | 0.010 |
Why?
|
| Mass Chest X-Ray | 1 | 1983 | 6 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1983 | 32 | 0.010 |
Why?
|
| Blood Pressure Monitors | 1 | 2003 | 9 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2003 | 34 | 0.010 |
Why?
|
| Pedigree | 1 | 2005 | 966 | 0.010 |
Why?
|
| Ion Channels | 1 | 1985 | 246 | 0.010 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1982 | 6 | 0.010 |
Why?
|
| Levorphanol | 1 | 1982 | 3 | 0.010 |
Why?
|
| DNA | 1 | 2009 | 1294 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1982 | 27 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 122 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 62 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1983 | 69 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1983 | 218 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 574 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 570 | 0.010 |
Why?
|
| Prejudice | 1 | 2002 | 49 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 1074 | 0.010 |
Why?
|
| Receptors, Opioid | 1 | 1982 | 24 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 1983 | 126 | 0.010 |
Why?
|
| Cornell Medical Index | 1 | 1981 | 1 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2378 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1981 | 108 | 0.010 |
Why?
|
| Serotonin | 1 | 1982 | 218 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1982 | 283 | 0.010 |
Why?
|
| Self Administration | 1 | 2000 | 73 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1980 | 83 | 0.010 |
Why?
|
| Drinking | 1 | 1999 | 34 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1999 | 62 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2000 | 369 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 394 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 1983 | 413 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2216 | 0.010 |
Why?
|
| Psoriasis | 1 | 1980 | 240 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1992 | 72 | 0.010 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 1991 | 10 | 0.010 |
Why?
|
| Peritonitis | 1 | 1991 | 29 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1991 | 102 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1991 | 244 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 378 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 927 | 0.010 |
Why?
|
| Steroids | 1 | 1990 | 177 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1991 | 255 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1987 | 14 | 0.000 |
Why?
|
| Base Sequence | 1 | 1992 | 2330 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1987 | 197 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 1135 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 3030 | 0.000 |
Why?
|
| Body Fluids | 1 | 1982 | 36 | 0.000 |
Why?
|
| Haplorhini | 1 | 1982 | 81 | 0.000 |
Why?
|
| Chromatography, Liquid | 1 | 1982 | 104 | 0.000 |
Why?
|